Antiangiogenic agents in the treatment of nonsmall cell lung cancer: Reality and hope

Current Opinion in Oncology

Volumn 22, Issue 2, 2010, Pages 79-85

  Ramalingam, Suresh S ^a   Belani, Chandra P ^b  

^a EMORY UNIVERSITY   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenic therapy; Bevacizumab; Biomarkers; Non small cell lung cancer

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; LINIFANIB; MOTESANIB; PACLITAXEL; PEMETREXED; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

ADD ON THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG SAFETY; FATIGUE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 76749157944     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328335a583     Document Type: Review

References (47)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
2. Dvorak HF, SioussatTM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991; 174:1275-1278.
3. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77:527-543. (Pubitemid 29426311)
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
5. Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004; 31 (Suppl 1):68-74.
6. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer. N Engl J Med 2004; 350:351-360.
7. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III nonsmall-cell lung cancer. N Engl J Med 1990; 323:940-945.
8. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and over-expression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86:558-563.
9. Socinski MA, NovelloS, BrahmerJR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced nonsmall-cell lung cancer. J Clin Oncol 2008; 26:650-656.
10. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced nonsmall-cell lung cancer. J Clin Oncol 2009; 27: 4274-4280.
11. Ramalingam S, Belani CP. Role of bevacizumab for the treatment of nonsmall-cell lung cancer. Future Oncol 2007; 3:131-139.
12. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
14. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
15. Hanna N, Von Pawel J, Reck M, Scagliotti G. Carboplatin/paclitaxel with/ without sorafenib in chemonaive patients with stage IIIB-IV nonsmall cell lung cancer: interim analysis from a randomized phase III trial (ESCAPE) [abstract #13]. J Thorac Oncol 2008; 3:S268.
16. Blumenschein G, Kabbinavar F, Memon H, et al. Randomized, open-label phase 2 study of safety and efficacy of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous nonsmall cell lung cancer [abstract #C1.4]. J Thorac Oncol 2009; 4:S354.
17. Laurie S, Arnold A, Shepherd F, et al. Randomized, double-blind phase II trial of carboplatin, paclitaxel with either daily oral cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced nonsmall cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group [abstract #231PD]. Ann Oncol 2008; 19 (Suppl 8):290.
18. Herbst R, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced nonsmall cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC) [abstract #8003]. J Clin Oncol 2009; 27 (15 Suppl).
19. De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced nonsmall cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL) [abstract #8010]. J Clin Oncol 2009; 27 (15 Suppl).
20. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with nonsmall-cell lung cancer and brain metastases. J Clin Oncol 2009; 27:5255-5261.
21. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizu mab as first-line therapy for nonsquamous nonsmall-cell lung cancer. J Clin Oncol 2009; 27:3284-3289.
22. Kris M, Price K, Rusch V, et al. Phase II trial of induction and adjuvant bevacizumab with cisplatin and docetaxel in patients with locally advanced nonsmall cell lung cancer [abstract #C6.3]. J Thorac Oncol 2009; 4:S372.
23. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60-65.
24. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2009 Nov. 9. [Epub ahead of print]
25. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib com pared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25:4743-4750.
26. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab in combination with erlotinib compared with erlotinib alone for treatment of advanced nonsmall cell lung cancer after failure of standard first-line chemotherapy (BETA). J Thorac Oncol 2008; 3 (Suppl 4):S302.
27. Spigel DR, Greco A, Burris H, et al. A randomized double-blind placebo-controlled phase II trial of sorafenib and erlotinib or erlotinib in previously treated advanced nonsmall cell lung cancer [abstract #C1.5]. J Thorac Oncol 2009; 4:S355.
28. Miller V, O'Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic nonsmall cell lung cancer (NSCLC) [abstract #8002]. J Clin Oncol 2009; 27 (15 Suppl).
29. Schiller JH, Larson T, Ou SH, et al. Efficacy and safety of axitinib in patients with advanced nonsmall-cell lung cancer: results from a phase II study. J Clin Oncol 2009; 27:3836-3841.
30. Natale RB, Bodkin D,Govindan R, et al. Vandetanib versus gefitinib in patients with advanced nonsmall-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009; 27:2523-2529.
31. Gauler T, Besse B, Meric J, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV nonsmall cell lung cancer (NSCLC) [abstract #7541]. J Clin Oncol 2007; 25 (18 Suppl).
32. Tan EH, Salgia R, Besse B, et al. ABT-869 in nonsmall cell lung cancer: Interim results [abstract #8074]. J Clin Oncol 2009; 27 (15 Suppl).
33. Schiller J, LeeJW, HannaN, et al.A randomized discontinuation phase II study of sorafenib versus placebo in patients with nonsmall cell lung cancer who have failed at least two prior chemotherapy regimens (ECOG 2501) [abstract 8014]. J Clin Oncol 2008; 26 (15 Suppl):8427s.
34. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced nonsmall-cell lung cancer. J Clin Oncol 2008; 26:5407-5415.
35. Natale NB, Thongprasert S, Greco A, et al. Vandetanib versus erlotinib in patients with advanced nonsmall cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST) [abstract #8009]. J Clin Oncol 2009; 27 (15 Suppl).
36. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with nonsmall cell lung cancer treated with chemotherapy with or without bev-acizumab: an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14:1407-1412.
37. Heymach J, Hanrahan E, Mann H, et al. Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC [abstract #8009]. J Clin Oncol 2008; 26 (15 Suppl).
38. Norden-Zfoni A, Desai J, ManolaJ, et al. Blood-based biomarkersof SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13:2643-2650.
39. Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11:3514-3522.
40. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26:4672-4678.
41. Zhang W, Dahlberg S, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599 [abstract #8032]. J Clin Oncol 2009; 27 (15 Suppl).
42. Ebos JM, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104:17069-17074.
43. Kono SA, Marshall ME, Ware KE, Heasley LE. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in nonsmall cell lung cancer. Drug Resist Update 2009; 12 (4-5):95-102.
44. Takahama M, Tsutsumi M, Tsujiuchi T, et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human nonsmall cell lung carcinomas. Clin Cancer Res 1999; 5:2506-2510.
45. Naumnik W, Chyczewska E, Ossolinska M. Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy. Cancer Invest 2009; 27:741-746.
46. Ng QS, Goh V, Carnell D, et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67:1375-1380.
47. Rehman F, Rustin G. ASA404: update on drug development. Expert Opin Investig Drugs 2008; 17:1547-1551.